Jim Cramer Reevaluates Novo Nordisk (NVO) as Wegovy Pill Adoption Accelerates

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) have experienced significant volatility after delivering strong quarterly results. On August 12, Jim Cramer highlighted the disconnect between the company's impressive performance and Wall Street's initial negative reaction. Despite reporting a beat and raise in earnings, Novo Nordisk's stock fell nearly 6% on the day.

Since then, the stock has largely recovered its losses. Novo Nordisk is credited with inventing the GLP-1 category, and their obesity and diabetes businesses are now generating substantial revenue. In January, they launched an oral version of Wegovy, which has already been prescribed to over 5 million patients, primarily those who had not tried injectable treatments.

This shift in treatment preferences has challenged Cramer's previous bearish stance on the stock. In his most recent commentary, Cramer expressed a more positive outlook, acknowledging Novo Nordisk's potential as an investment, though he still believes that other AI stocks may offer greater upside potential with less downside risk.